-
Product Insights
Net Present Value Model: NewAmsterdam Pharma Company NV’s Obicetrapib
Empower your strategies with our Net Present Value Model: NewAmsterdam Pharma Company NV's Obicetrapib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Obicetrapib in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Obicetrapib in Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obicetrapib in Dyslipidemia Drug Details: Obicetrapib (AMG-899, DEZ-001, TA-8995) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Obicetrapib in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Obicetrapib in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obicetrapib in Alzheimer's Disease Drug Details: Obicetrapib (AMG-899, DEZ-001, TA-8995) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ribociclib Succinate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ribociclib Succinate in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ribociclib Succinate in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Clascoterone in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Clascoterone in Pancreatic Cancer Drug Details: Clascoterone (Winlevi) is a cortexolone 17alpha-propionate derivative acts as...
-
Product Insights
Atherosclerosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Atherosclerosis - Drugs In Development, 2023’, provides an overview of the Atherosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Arteriosclerosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Arteriosclerosis - Drugs In Development, 2023’, provides an overview of the Arteriosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arteriosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...